Servatus launches new trial into the effects of live biotherapeutics on insomniaServatus launches new trial into the effects of live biotherapeutics on insomnia, we talk to CEO Dr Wayne Finlayson to discuss this exciting initiative. Posted on March 24th, 2022 . Updated on April 11th, 2022 by Michael LoveseyServatus CEO Dr Wayne Finlayson discusses the company’s new human clinical trial into the link between the gut microbiome and sleep by treating patients who suffer from insomnia with live biotherapeutics